3 recruiting, 2 unknown, 1 terminated. 3 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Unknown 1 |
Follow High-dose Methotrexate: new trials by email Literature Review of High-dose Methotrexate trials Research Report on High-dose Methotrexate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma High-dose Methotrexate - Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults | Phase 2 | Recruiting | Wake Forest University Health Sciences | 46 | 2026-09-01 | 2026-10-13 |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
| Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1800 | 2025-01-03 | 2026-07-23 |
| Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate High-dose methotrexate, Glucarpidase - Acute Kidney Injury, Drug Toxicity | Unknown | Protherics Medicines Development Limited | 1000 | 2022-04-01 | 2024-05-10 | |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2016-11-23 | 2019-04-03 |
| Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008 PEG-L-asparaginase ind, PEG-L-asparaginase cons, E.coli L-asparaginase - Childhood Acute Lymphoblastic Leukemia | Not applicable | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 3000 | 2008-02-01 | 2020-02-05 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Osteosarcoma (2) · Acute Kidney Injury (1) · Burkitt Lymphoma (1) · Drug-Related Side Effects and Adverse Reactions (1) · Epstein-Barr Virus Infections (1) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1) · Leukemia, T-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Water Intoxication (1)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Protherics Medicines Development Limited (1) · Rong Tao (1) · St. Jude Children's Research Hospital (1) · Wake Forest University Health Sciences (1)
China (2) · United States (2) · Belarus (1) · France (1) · Hong Kong (1) · Italy (1) · Russia (1) · Spain (1) · Uzbekistan (1)
Alexander I. Karachunskiy, Professor (1) · Carmelo Rizzari, MD (1) · Chuanxu Liu, MD & PhD (1) · Rong Tao, MD & PhD (1) · Sima Jeha, MD (1) · Thomas Russell, MD (1) · Xiaofan Zhu, MD (1)
PMID 25113753, PMID 34806163, PMID 35489026, PMID 35732829, PMID 38651186, PMID 41774854